News

Following INGN 225 treatment and chemotherapy, 62% of evaluable patients demonstrated objective tumor responses. Historically, response rates to second line chemotherapy in this disease range from only 5-25%.

If successfully developed, this oral formulation may support the evaluation of Telintra in additional hematologic disorders characterized by low levels of one or more of the three blood

The advisory committee recommended that the oral, three-dose vaccine be given during the current routine ‘well-baby’ visits at two, four, and six months of age. On February 3,

The collaboration will bring together the complementary know-how of both companies in miRNA and leverage Rosetta’s database of novel miRNA genes and Isis’ expertise in oligonucleotide chemistry and

According to Pfizer, candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40%. In the US, candidemia affects approximately one

Pre-clinical data for Lovaxin C demonstrates an extremely robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the

In the trials, drug resistance will be evaluated using Monogram’s PhenoSense GT, as well as other phenotypic and genotypic assays and clinical trial services. MK-0518 is a novel

In previous experimental studies the candidate, CTCE-9908, has been shown to reduce cancer metastases by a considerable 50-70%. CTCE-9908 targets the CXCR4 receptor and is part of a

A total of 196 healthy subjects have been exposed to DG041 at doses up to 1600 mg per day for seven days. As well as the encouraging safety